Literature DB >> 22875616

Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine.

Mathilde Gavillet, Jasmine Noetzli, Sabine Blum, Michel A Duchosal, Olivier Spertini, Jean-Francois Lambert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22875616      PMCID： PMC3590099          DOI： 10.3324/haematol.2012.065151

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

Review 1.  New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome.

Authors:  Steven D Gore
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Authors:  Jan J Cornelissen; Wim L J van Putten; Leo F Verdonck; Matthias Theobald; Emanuel Jacky; Simon M G Daenen; Marinus van Marwijk Kooy; Pierre Wijermans; Harry Schouten; Peter C Huijgens; Hans van der Lelie; Martin Fey; Augustin Ferrant; Johan Maertens; Alois Gratwohl; Bob Lowenberg
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

3.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

4.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Authors:  Lewis R Silverman; David R McKenzie; Bercedis L Peterson; James F Holland; Jay T Backstrom; C L Beach; Richard A Larson
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

5.  Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Authors:  Raphael Itzykson; Sylvain Thépot; Bruno Quesnel; Francois Dreyfus; Odile Beyne-Rauzy; Pascal Turlure; Norbert Vey; Christian Recher; Caroline Dartigeas; Laurence Legros; Jacques Delaunay; Célia Salanoubat; Sorin Visanica; Aspasia Stamatoullas; Francoise Isnard; Anne Marfaing-Koka; Stephane de Botton; Youcef Chelghoum; Anne-Laure Taksin; Isabelle Plantier; Shanti Ame; Simone Boehrer; Claude Gardin; C L Beach; Lionel Adès; Pierre Fenaux
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.

Authors:  Lewis R Silverman
Journal:  Leuk Res       Date:  2009-12       Impact factor: 3.156

8.  Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.

Authors:  H Tilly; S Castaigne; D Bordessoule; P Casassus; P Y Le Prisé; G Tertian; B Desablens; M Henry-Amar; L Degos
Journal:  J Clin Oncol       Date:  1990-02       Impact factor: 44.544

9.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

10.  Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.

Authors:  Roger M Lyons; Thomas M Cosgriff; Sanjiv S Modi; Robert H Gersh; John D Hainsworth; Allen L Cohn; Heidi J McIntyre; Indra J Fernando; Jay T Backstrom; C L Beach
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
View more
  8 in total

1.  Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.

Authors:  Neha Gupta; Austin Miller; Shipra Gandhi; Laurie A Ford; Carlos E Vigil; Elizabeth A Griffiths; James E Thompson; Meir Wetzler; Eunice S Wang
Journal:  Am J Hematol       Date:  2015-07       Impact factor: 10.047

2.  Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.

Authors:  Sara Pepe; Emilia Scalzulli; Gioia Colafigli; Alessio Di Prima; Daniela Diverio; Marco Mancini; Roberto Latagliata; Maurizio Martelli; Robin Foà; Massimo Breccia
Journal:  Ann Hematol       Date:  2020-08-19       Impact factor: 3.673

3.  Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.

Authors:  Lisa Pleyer; Reinhard Stauder; Sonja Burgstaller; Martin Schreder; Christoph Tinchon; Michael Pfeilstocker; Susanne Steinkirchner; Thomas Melchardt; Martina Mitrovic; Michael Girschikofsky; Alois Lang; Peter Krippl; Thamer Sliwa; Alexander Egle; Werner Linkesch; Daniela Voskova; Hubert Angermann; Richard Greil
Journal:  J Hematol Oncol       Date:  2013-04-29       Impact factor: 17.388

4.  Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

Authors:  Eytan M Stein; Courtney D DiNardo; Amir T Fathi; Daniel A Pollyea; Richard M Stone; Jessica K Altman; Gail J Roboz; Manish R Patel; Robert Collins; Ian W Flinn; Mikkael A Sekeres; Anthony S Stein; Hagop M Kantarjian; Ross L Levine; Paresh Vyas; Kyle J MacBeth; Alessandra Tosolini; Jason VanOostendorp; Qiang Xu; Ira Gupta; Thomas Lila; Alberto Risueno; Katharine E Yen; Bin Wu; Eyal C Attar; Martin S Tallman; Stéphane de Botton
Journal:  Blood       Date:  2018-12-03       Impact factor: 25.476

5.  Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.

Authors:  Lisa Pleyer; Sonja Burgstaller; Michael Girschikofsky; Werner Linkesch; Reinhard Stauder; Michael Pfeilstocker; Martin Schreder; Christoph Tinchon; Thamer Sliwa; Alois Lang; Wolfgang R Sperr; Peter Krippl; Dietmar Geissler; Daniela Voskova; Konstantin Schlick; Josef Thaler; Sigrid Machherndl-Spandl; Georg Theiler; Otto Eckmüllner; Richard Greil
Journal:  Ann Hematol       Date:  2014-06-21       Impact factor: 3.673

6.  Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.

Authors:  Lisa Pleyer; Sonja Burgstaller; Reinhard Stauder; Michael Girschikofsky; Heinz Sill; Konstantin Schlick; Josef Thaler; Britta Halter; Sigrid Machherndl-Spandl; Armin Zebisch; Angelika Pichler; Michael Pfeilstöcker; Eva-Maria Autzinger; Alois Lang; Klaus Geissler; Daniela Voskova; Dietmar Geissler; Wolfgang R Sperr; Sabine Hojas; Inga M Rogulj; Johannes Andel; Richard Greil
Journal:  J Hematol Oncol       Date:  2016-04-16       Impact factor: 17.388

7.  Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies.

Authors:  Jonathan Feld; Douglas Tremblay; Mikaela Dougherty; Tina Czaplinska; Gillian Sanchez; Claudia Brady; Marina Kremyanskaya; Michal Bar-Natan; Alla Keyzner; Bridget K Marcellino; Janice Gabrilove; Shyamala C Navada; Lewis R Silverman; Siraj M El Jamal; John Mascarenhas; Alan H Shih
Journal:  Hemasphere       Date:  2021-03-09

8.  Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2.

Authors:  Ritika Dutta; Tian Yi Zhang; Thomas Köhnke; Daniel Thomas; Miles Linde; Eric Gars; Melissa Stafford; Satinder Kaur; Yusuke Nakauchi; Raymond Yin; Armon Azizi; Anupama Narla; Ravindra Majeti
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 19.456
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.